Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease

References

• GoASChertowGMFanDMcCullochCEHsuCYChronic kidney disease and the risks of death, cardiovascular events, and hospitalizationN Engl J Med2004351131296130515385656
   PubMed Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative, National Kidney FoundationKDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney diseaseAm J Kidney Dis2006475 Suppl 3S11S14516678659
   PubMed Web of Science ®Google Scholar
• SilverbergDSWexlerDShepsDThe effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled studyJ Am Coll Cardiol20013771775178011401110
   PubMed Web of Science ®Google Scholar
• HalstensonCEMacresMKatzSAComparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin betaClin Pharmacol Ther19915067027121752115
   PubMed Web of Science ®Google Scholar
• RobinsonDMEasthopeSEDarbepoetin alfa: its use in anemia associated with chronic kidney diseaseBio Drugs2005195327343
   Google Scholar
• PadhiDNiLCookeBMarinoRJangGAn extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysisClin Pharmacokinet200645550351016640455
   PubMed Web of Science ®Google Scholar
• MacdougallICGraySJElstonOPharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patientsJ Am Soc Nephrol199910112392239510541299
   PubMed Web of Science ®Google Scholar
• MacdougallICRobsonROpatrnaSPharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney diseaseClin J Am Soc Nephrol2006161211121517699350
   PubMed Web of Science ®Google Scholar
• MacdougallICEckardtKUNovel strategies for stimulating erythropoiesis and potential new treatments for anaemiaLancet2006368953994795316962885
   PubMed Web of Science ®Google Scholar
• JarschMBrandtMLanzendörferMHaselbeckAComparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assayPharmacology2008811636917901722
   PubMed Web of Science ®Google Scholar
• FishbaneSPannierALiogierXJordanPDoughertyFCReignerBPharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administrationJ Clin Pharmacol200747111390139717962427
   PubMed Web of Science ®Google Scholar
• de FranciscoALSulowiczWKlingerMBA16260 Study InvestigatorsContinuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II studyInt J Clin Pract200660121687169617109676
   PubMed Web of Science ®Google Scholar
• BesarabASalifuMOLundeNMBa16285 Study InvestigatorsEfficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal diseaseClin Ther200729462663917617286
   PubMed Web of Science ®Google Scholar
• LocatelliFVillaGde FranciscoALBA16286 Study InvestigatorsEffect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administrationCurr Med Res Opin200723596997917519064
   PubMed Web of Science ®Google Scholar
• ProvenzanoRBesarabAMacdougallICBA 16528 Study InvestigatorsThe continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II studyClin Nephrol200767530631717542340
   PubMed Web of Science ®Google Scholar
• KlingerMAriasMVargemezisVEfficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trialAm J Kidney Dis2007506989100018037099
   PubMed Web of Science ®Google Scholar
• MacdougallICWalkerRProvenzanoRARCTOS Study InvestigatorsC.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trialClin J Am Soc Nephrol20083233734718287255
   PubMed Web of Science ®Google Scholar
• LevinNWFishbaneSCañedoFVMAXIMA Study InvestigatorsIntravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)Lancet200737095961415142117950856
   PubMed Web of Science ®Google Scholar
• SulowiczWLocatelliFRyckelynckJPPROTOS Study InvestigatorsOnce-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weeklyClin J Am Soc Nephrol20072463764617699476
   PubMed Web of Science ®Google Scholar
• CanaudBMingardiGBraunJSTRIATA Study InvestigatorsIntravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III studyNephrol Dial Transplant200823113654366118586762
   PubMed Web of Science ®Google Scholar
• SpinowitzBCoyneDWLokCERUBRA Study InvestigatorsC.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeksAm J Nephrol200828228028918004064
   PubMed Web of Science ®Google Scholar
• CarreraFLokCEde FranciscoAPATRONUS InvestigatorsMaintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trialNephrol Dial Transplant201025124009401720522670
   PubMed Web of Science ®Google Scholar
• FliserDKleophasWDellannaFEvaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL studyCurr Med Res Opin20102651083108920225992
   PubMed Web of Science ®Google Scholar
• van der PuttenKBraamBJieKEGaillardCAMechanisms of disease: erythropoietin resistance in patients with both heart and kidney failureNat Clin Pract Nephrol200841475718094727
   PubMedGoogle Scholar
• FishbaneSBernsJSHemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietinKidney Int20056831337134316105069
   PubMed Web of Science ®Google Scholar
• SelbyNMFonsecaSFluckRTaalMWHemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysisPerit Dial Int201232217718222045101
   PubMed Web of Science ®Google Scholar
• MIRCERA^®: methoxy polyethylene glycol-epoetin beta [product information]Dee Why, AustraliaRoche2010 Available from: http://www.roche-australia.com/fmfiles/re7229005/downloads/anaemia/mircera-pi.pdfAccessed March 23, 2012
   Google Scholar
• PannierAJordanPDoughertyFCBourFReignerBSubcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfaCurr Med Res Opin200723123025303217961301
   PubMed Web of Science ®Google Scholar
• SaueressigUKwanJTDe CockESapèdeCHealthcare resource utilization for anemia management: current practice with erythropoiesis- stimulating agents and the impact of converting to once-monthly C.E.R.ABlood Purif200826653754618997465
   PubMed Web of Science ®Google Scholar
• RocheMicera^® solution for injection in pre-filled syringe [summary of product characteristics]Welwyn Garden CityRoche Ltd2012 Available from: http://www.medicines.org.uk/emc/medicine/19960/SPC/Accessed February 21, 2012
   Google Scholar
• LocatelliFAljamaPBárányPEuropean Best Practice Guidelines Working GroupRevised European best practice guidelines for the management of anaemia in patients with chronic renal failureNephrol Dial Transplant200419Suppl 2ii1ii4715206425
   PubMedGoogle Scholar